Recent advances in lung-on-a-chip models

Drug Discovery Today, Journal Year: 2022, Volume and Issue: 27(9), P. 2593 - 2602

Published: June 18, 2022

Language: Английский

---

Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2023, Volume and Issue: 397(5), P. 2793 - 2833

Published: Nov. 22, 2023

Language: Английский

---

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery

Polymers, Journal Year: 2023, Volume and Issue: 15(18), P. 3849 - 3849

Published: Sept. 21, 2023

The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes death worldwide. In this sense, in addition to high prevalence such asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging diseases, particularly those caused by members coronavirus family, have contributed significant number deaths on global scale over last two decades. Therefore, several studies been conducted optimize efficacy treatments against these focusing drug delivery using nanomedicine. Thus, development nanocarriers has emerged promising alternative overcome limitations conventional therapy, increasing bioavailability at target site reducing unwanted side effects. context, nanoparticles composed chitosan (CS) show advantages other because possesses intrinsic biological properties, anti-inflammatory, antimicrobial, mucoadhesive capacity. Moreover, CS potential enhance stability, prolong duration action, improve targeting, control release, dissolution poorly soluble drugs, increase cell membrane permeability hydrophobic drugs. These properties could performance after its administration. review aims discuss for delivery, highlighting how their can treatment including synergistic action with encapsulated drug.

Language: Английский

---

Evaluation of the Cytotoxic Activity and Anti-Migratory Effect of Berberine–Phytantriol Liquid Crystalline Nanoparticle Formulation on Non-Small-Cell Lung Cancer In Vitro

Pharmaceutics, Journal Year: 2022, Volume and Issue: 14(6), P. 1119 - 1119

Published: May 24, 2022

Non-small-cell lung cancer (NSCLC) is the most common form of cancer, which a leading cause cancer-related deaths worldwide. Berberine an isoquinoline alkaloid that commercially available for use as supplement treatment diabetes and cardiovascular diseases. However, therapeutic benefits berberine are limited by its extremely low bioavailability toxicity at higher doses. Increasing evidence suggests incorporation drug compounds in liquid crystal nanoparticles provides new platform safe, effective, stable, controlled delivery molecules. This study aimed to formulate optimized formulation berberine–phytantriol-loaded crystalline (BP-LCNs) investigate vitro anti-cancer activity human adenocarcinoma A549 cell line. The BP-LCN possessing optimal characteristics was used this had favorable particle size entrapment efficiency rate (75.31%) superior release profile. potential mechanism action determined measuring mRNA levels tumor-associated genes PTEN, P53, KRT18 protein expression with oncology array. BP-LCNs decreased proliferation, migration, colony-forming cells dose-dependent manner upregulating PTEN P53 downregulating KRT18. Similarly, also proteins related proliferation migration. highlights utility phytantriol-based LCNs incorporating molecules GI absorption increase their pharmacological effectiveness potency NSCLC.

Language: Английский

---

Targeting the mitochondria in chronic respiratory diseases

Mitochondrion, Journal Year: 2022, Volume and Issue: 67, P. 15 - 37

Published: Sept. 20, 2022

Language: Английский

---

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis

Journal of Personalized Medicine, Journal Year: 2022, Volume and Issue: 12(8), P. 1321 - 1321

Published: Aug. 16, 2022

The development of preclinical in vitro models has provided significant progress to the studies cystic fibrosis (CF), a frequently fatal monogenic disease caused by mutations gene encoding CF transmembrane conductance regulator (CFTR) protein. Numerous cell lines were generated over last 30 years and they have been instrumental not only enhancing understanding pathological mechanisms but also developing therapies targeting underlying defects CFTR with further validation patient-derived samples. Furthermore, recent advances toward precision medicine made possible optimizing protocols establishing novel assays using human bronchial, nasal rectal tissues, progressing from two-dimensional monocultures more complex three-dimensional culture platforms. These enable potentially predict clinical efficacy responsiveness modulator at an individual level. In parallel, advanced systems, such as induced pluripotent stem cells organ-on-a-chip, continue be developed order closely recapitulate physiology for modeling drug testing. this review, we highlighted optimized that are being used research develop CFTR-directed (or alternative therapeutic interventions) expand usage existing drugs common rare CF-causing mutations.

Language: Английский

---

Progress and application of lung-on-a-chip for lung cancer

Frontiers in Bioengineering and Biotechnology, Journal Year: 2024, Volume and Issue: 12

Published: May 24, 2024

Lung cancer is a malignant tumour with the highest incidence and mortality worldwide. Clinically effective therapy strategies are underutilized owing to lack of efficient models for evaluating drug response. One main reasons failure anticancer development resistance. Anticancer drugs face severe challenges such as poor biodistribution, restricted solubility, inadequate absorption, accumulation. In recent years, “organ-on-a-chip” platforms, which can directly regulate microenvironment biomechanics, biochemistry pathophysiology, have been developed rapidly shown great potential in clinical research. Lung-on-a-chip (LOC) new 3D model bionic lungs physiological functions created by micromachining technology on microfluidic chips. This approach may be able partially replace animal 2D cell culture models. To overcome resistance, LOC realizes personalized prediction response simulating lung-related vitro , significantly enhancing therapeutic effectiveness, bioavailability, pharmacokinetics while minimizing side effects. this review, we present an overview advances preparation contrast it earlier Finally, describe LOC. The combination nanomedicine will provide accurate reliable treatment preclinical evaluation.

Language: Английский

---

Berberine-loaded engineered nanoparticles attenuate TGF-β-induced remodelling in human bronchial epithelial cells

Toxicology in Vitro, Journal Year: 2023, Volume and Issue: 92, P. 105660 - 105660

Published: Aug. 15, 2023

Language: Английский

---

Plant-based therapeutics for chronic obstructive pulmonary diseases: Nanoformulation strategies to overcome delivery challenges

Food Bioscience, Journal Year: 2024, Volume and Issue: 58, P. 103761 - 103761

Published: Feb. 16, 2024

Chronic obstructive pulmonary disease (COPD) is a widespread global health problem marked by increasing airflow limitation and chronic airway inflammation. Conventional treatments for COPD offer limited efficacy have potentially undesirable effects, requiring the investigation of other therapeutic options. Because their anti-inflammatory, antioxidant, bronchodilatory plant-based chemicals emerged as viable candidates therapy. The successful delivery these compounds to respiratory system, on hand, remains an enormous challenge. This extensive review article explores promising potential therapies investigates leading-edge nanoformulation technologies targeted at addressing complex challenges that accompany natural compounds. We discuss multiple plant-derived (polyphenols, flavonoids, alkaloids) modes action in reducing COPD-related indications complications. Additionally, function nanotechnology improving bioavailability, stability, pharmaceuticals treatment explored. Nanoformulation techniques, such nanoparticles, liposomes, micelles, are described, with emphasis precisely encapsulate transport bioactive afflicted parts lung. Furthermore, constraints development nanoformulations also highlighted, including safety, scalability, regulatory issues. current aims provide thorough understanding future combining knowledge novel technologies. intersection nature-inspired medicines may hold key more effective, safer, patient-centred choices people suffering from this illness.

Language: Английский

---

Nutraceuticals and mitochondrial oxidative stress: bridging the gap in the management of bronchial asthma

Environmental Science and Pollution Research, Journal Year: 2022, Volume and Issue: 29(42), P. 62733 - 62754

Published: July 7, 2022

Abstract Asthma is a chronic inflammatory disease primarily characterized by inflammation and reversible bronchoconstriction. It currently one of the leading causes morbidity mortality in world. Oxidative stress further complicates pathology disease. The current treatment strategies for asthma mainly involve use anti-inflammatory agents bronchodilators. However, long-term usage such medications associated with severe adverse effects complications. Hence, there an urgent need to develop newer, novel, safe modalities management asthma. This has therefore prompted investigations detailed research identify novel therapeutic interventions from potent untapped resources. review focuses on significance oxidative stressors that are derived both mitochondrial non-mitochondrial sources initiating clinical features also discusses biological scavenging system body factors may lead its malfunction which could result altered states. Furthermore, provides insight into role nutraceuticals as effective strategy attenuate deleterious be used mitigation cardinal bronchial

Language: Английский

---